A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
NCT ID: NCT01876251
Last Updated: 2019-03-15
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
30 participants
INTERVENTIONAL
2013-11-04
2015-12-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.
NCT00471159
Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer
NCT00002662
Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT00461344
Doxorubicin in Treating Women With Advanced Breast Cancer
NCT00003165
A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer
NCT01740336
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PF-03084014 plus docetaxel
PF 03084014 will be administered orally, continuously, twice daily at doses from 80 to 150 mg in combination with docetaxel given every 3 weeks at doses from 75 to 100 mg/m\^2
PF-03084014
Tablet, 10 mg, twice a day
PF-03084014
Tablet, 50 mg, twice a day
PF-03084014
Tablet, 100 mg, twice a day
Docetaxel
Solution for IV infusion 75 mg/m\^2, every 3 weeks
Docetaxel
Solution for IV infusion 100 mg/m\^2, every 3 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PF-03084014
Tablet, 10 mg, twice a day
PF-03084014
Tablet, 50 mg, twice a day
PF-03084014
Tablet, 100 mg, twice a day
Docetaxel
Solution for IV infusion 75 mg/m\^2, every 3 weeks
Docetaxel
Solution for IV infusion 100 mg/m\^2, every 3 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
University of Alabama at Birmingham, IDS Pharmacy
Birmingham, Alabama, United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Stanford Cancer Institute
Stanford, California, United States
Stanford Hospital & Clinics-DRUG SHIPMENT ADDRESS only
Stanford, California, United States
Stanford Hospital & Clinics
Stanford, California, United States
Stanford Women's Cancer Center
Stanford, California, United States
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
Karmanos Cancer Institute (KCI)
Detroit, Michigan, United States
UNC Cancer Hospital Infusion Pharmacy
Chapel Hill, North Carolina, United States
UNC Hospitals, The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Jules Bordet Institut
Brussels, , Belgium
Grand Hopital de Charleroi
Charleroi, , Belgium
Instituto Europeo di Oncologia
Milan, , Italy
Instituto Catalan de Oncologia de L'Hospitalet de Llobregat(ICO)
Barcelona, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-000659-41
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
A8641016
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.